Skip to main content

Table 1 Characteristics of the eligible clinical trials

From: Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials

Author and Year Study phase Country Study design Stage N EGFRm+ (%) Adjuvant CT (%) Intervention Duration (months) Endpoints Follow-up (months) mDFS (months) DFS rate DFS HR (95% CI) OS HR (95% CI)
N Regimes
Tada 2022 (IMPACT) Phase 3 Japan RCT II-III 232 100% 0% 116 Gefitinib 24 DFS 70 35.9 31.8%(5y) 0.92 (0.67–1.28) 1.03 (0.65–1.65)
100% 100% 116 NP    25.1 34.1%(5y)
He 2021 (EVIDENCE) Phase 3 China RCT II-IIIA 283 100% 0% 151 Icotinib 22.2 DFS 24.9 47 63.9%(3y) 0.36 (0.24–0.55) 0.91 (0.42–1.94)
100% 100% 132 NP/PP   22.1 32.5%(3y)
Wu 2020 (ADAURA) Phase 3 International RCT IB-IIIA 682 100% 76% (II-IIA), 26%(IB) 339 Osimertnib 36 DFS in II-IIIA 22.1 NR 90%(2y) 0.17 (0.11–0.26) 0.40 (0.09–1.83)
100% 343 Placebo    19.6 44%(2y)
Zhong 2018/2021 (ADJUVANT) Phase 3 China RCT II-IIIA 222 100% 0% 111 Gefitinib 24 DFS, OS 80.0 30.8 39.6%(3y) 22.6%(5y) 0.56 (0.40–0.79) 0.92 (0.62–1.36)
100% 100% 111 NP   19.8 32.5%(3y) 23.2%(5y)
Yue 2018 (EVAN) Phase 2 China RCT IIIA 102 100% 0% 51 Erlotinib 24 DFS, OS 33 42.4 81.4%(2y) 54.2%(3y) 0.27 (0.14–0.53) 0.165 (0.047–0.579)
100% 100% 51 NP   21 44.6%(2y) 19.8%(3y)
Kelly 2015 (RADIANT) Phase 3 International RCT IB-IIIA express EGFR 973 16.4% 50.6% 623 Erlotinib 24 DFS, OS in ITT 47 50.5 67.2%(2y) 0.90 (0.74–1.10) 1.13 (0.881–1.448)
16.9% 57.1% 350 Placebo   48.2 62.4%(2y)
161 100% 45.1% 102 Erlotinib 24 DFS, OS in EGFRm+ 47 46.4 75%(2y) 0.61 (0.384–0.981) 1.09 (0.555–2.161)
100% 55.9% 59 Placebo   28.5 54%(2y)
Feng 2015 NA China RCT IB-IIIA EGFRm+ 41 100% 100% 21 PTX + NDP/LP + Icotinib 4–8 DFS 24 NA 90.5%(2y) 0.45 (0.05–3.81) NA
100% 100% 20 PTX + NDP/LP   66.7%(2y)
Li 2014 Phase 2 China RCT IIIA-N2 60 100% 100% 30 PC + gefitinib 6 DFS, OS 30.6 39.8 78.9%(2y) 0.37 (0.16–0.85) 0.37 (0.12–1.11)
100% 100% 30 PC   27 54.2%(2y)
Goss 2013 (NCIC CTGBR19) Phase 3 North American RCT IB-IIIA 503 4% 17% 251 Gefitinib 24 OS, DFS 4.7 years 4.2 years 50.2%(4y) 1.22 (0.93–1.61); 1.84 (0.44–7.73) (EGFRm+) 1.24 (0.94–1.64); 3.16 (0.61–16.45) EGFRm+
4.3% 17% 252 Placebo NR 57.6%(4y)
  1. NP Vinorelbine + Cisplatin, PP Pemetrexed + Cisplatin, PTX Paclitaxel, NDP Nedaplatin, LP Lobaplatin, PC Pemetrexed + carboplatin, NA Not available, NR Not reached, N Number, CT Chemotherapy, RCT Randomized controlled trial, DFS Disease-free survival, mDFS Median disease-free survival, OS Overall survival, EGFRm+: Epidermal growth factor receptor mutation positive, ITT Intent-to-treat, HR Hazard ratio, CI Confidence interval